New hope for the tiniest malaria patients: a safer treatment for infants under 5 kg

NCT ID NCT07713602

Not yet recruiting Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests a specially formulated dispersible tablet, Coartem Baby, in infants weighing between 2 and 5 kg who have uncomplicated malaria. The goal is to see if the drug is safe and effectively clears symptoms like fever and chills. Twenty infants will receive the standard three-day treatment, and researchers will monitor for side effects and recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Coartem Baby (artemether/lumefantrine) dispersible tablets
What this could lead to: If successful, this could provide a safe and effective treatment option for the smallest infants with malaria, a group often excluded from studies.
What could go wrong: This is a small, early-phase study with only 20 participants and no comparison group, so results may not apply broadly. Side effects are possible, as with any medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria mixed malaria Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.